Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

Phibro Animal Health Corporation PAHC reported adjusted earnings per share (EPS) of 33 cents in the fourth quarter of fiscal 2019, showing a 28% drop from the year-ago number. The figure missed the Zacks Consensus Estimate by 2.9%.

Meanwhile, without adjustments, reported EPS was 22 cents, reflecting a fall of 60% from the year-ago count.

For fiscal 2019, adjusted EPS came in at $1.53, down 12% from the year-ago figure. The metric beat the consensus mark by 0.7%.

Net Sales

In the quarter under review, net sales totaled $203.9 million, down 3.7% year over year owing to substantially lower sales at two core segments — Animal Health and Mineral Nutrition.

For 2019, net sales totaled $828 million, up 1% from the year-ago tally. However, the figure missed the Zacks Consensus Estimate by 0.2%.

Phibro Animal Health Corporation Price, Consensus and EPS Surprise


Phibro Animal Health Corporation Price, Consensus and EPS Surprise

Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote


Segmental Sales Break-Up

During the fourth quarter, Animal Health net sales declined 4% to $132 million. Within this segment, the company registered $86.3 million in sales, reflecting a 6% decline in medicated feed additives (MFAs). This was on account of lower demand owing to African swine fever outbreak in China and consistently lower domestic demand from the poultry and swine sectors. Nutritional specialty product sales rose 1% to $28.6 million, asconsistently dismal domestic dairy conditions and lowered demand from poultry customers was offset by international volume growth in dairy products. Apart from this, net vaccine sales totaled $17.2 million, showing a drop of 1% year over year due to the loss of a domestic distribution arrangement and the continued impact of turbulent economic conditions in certain foreign markets.

Net sales at the Mineral Nutrition segment fell 7% year over year to $56 million owing tounfavorable product mix and lower average selling prices.

Net sales at the Performance Products segment rose 15% to $15.9 million backed by higher volumes of personal care products.

Operational Update

Phibro’s fourth-quarter gross profit declined 3.3% year over year to $65.3 million. Gross margin expanded 16 basis points (bps) to 32%.

Selling, general and administrative expenses in the reported quarter came in at $53.2 million, up 28.5% from the year-ago quarter.  

Operating profit declined 53.6% year over year to $12.1 million and operating margin contracted 639 bps to 5.9% in the quarter under review.

Financial Update

The company exited fiscal 2019 with net cash used by operating activities of $14.1 million, down from the year-ago $84.6 million. Capital expenditure amounted to $10.1 million in this quarter, reflecting an increase from $5.5 million in the prior-year quarter.

FY20 Outlook

The company has initiated its guidance for fiscal 2020. Net sales are projected in the range of $833-863 million (an increase of 1-4%). Adjusted EPS is estimated in the band of $1.08-1.15.

The Zacks Consensus Estimate for fiscal revenues 2020 is pegged at $862.6 million, within the guided range. The same for adjusted EPS is pegged at $1.61, above the guided range.

Our Take

Phibro ended fiscal 2019 on a disappointing note as earnings missed the consensus mark. Moreover, revenue decline across two of the core segments and contraction in operating margin are concerning. On an optimistic note, the company witnessed double-digit revenue growth at its Performance Products segment. Strong international volume growth in dairy products contributed to the rise in Nutritional specialty product sales. The company is upbeat about its long-term prospects within the animal health segment and has invested in strategic acquisitions like Osprey Biotechnics.

Zacks Rank and Key Picks

Phibro currently carries a Zacks Rank #3 (Hold).

A few better-ranked companies, which posted solid results this earnings season, are Stryker Corporation SYK, Baxter International Inc. BAX and Intuitive Surgical, Inc. ISRG.

Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion beat the consensus estimate of $2.79 billion by 1.9%. The company holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company carries a Zacks Rank of 2.

Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Revenues were $1.1 billion, surpassing the Zacks Consensus Estimate of $1.03 billion. The company has a Zacks Rank #2.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Click to get this free report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

Baxter International Inc. (BAX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More